CROSSJECT

Focus: CROSSJECT is a French biotechnology company specializing in needle-free injection technology, operating as a micro-cap biotech with 1-50 employees.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Employees

1-50

Open Jobs

About CROSSJECT

AI assessmentNot Hiring

No open roles listed right now. Follow CROSSJECT to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Intramuscular ZENEO® injection of nominal strength

No Condition

N/A

Clinical Trials (1)

NCT03225638Performance Evaluation by Magnetic Resonance Imaging (MRI) of Intramuscular Thigh Injections With 3 Configurations of Needle-free Injector (ZENEO®)

N/A

Help build intelligence for CROSSJECT

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage deep-tech platform in needle-free delivery with significant unmet market potential across multiple therapeutic areas
Opportunity to shape core technology and intellectual property strategy at a formative stage of company development
Location in Dijon, France provides access to strong regional biotech ecosystem and European regulatory pathways

Watch Out For

Micro-cap size (1-50 employees) means limited internal resources, mentorship infrastructure, and career development roles
No disclosed funding, revenue, or pipeline data indicates early pre-clinical stage with uncertain pathway to value creation and job security

Generated by Claude from CROSSJECT's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Ultrasound scans

Healthy Subjects

N/A

Clinical Trials (1)

NCT06279689Echography Study_Anthropometric Measurements

N/A

Injections in thigh of 0.625 mL of physiological serum with ZENEO® injector, on bare skin and through clothing.

Needle-free Injector

N/A

Clinical Trials (1)

NCT05967013Evaluation by Magnetic Resonance Imaging of Intramuscular Injections Performance in Thigh With 2 Configurations of the Needle-free Injector ZENEO®.

N/A

Intramuscular ZENEO® injection

No Condition

N/A

Clinical Trials (1)

NCT03044301Performance Thresholds Evaluation by Wet Injection Quantification and Magnetic Resonance Imaging (MRI) of Subcutaneous and Intramuscular Injections (0,65ml) of Several Configurations of Needle-free Devices (ZENEO®)

N/A

Zeneo® - Methotrexate

Healthy

Phase 1

Clinical Trials (1)

NCT03103334A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.

Phase 1

2 ml of DORMICUM® Midazolam Hydrochloride

Healthy

Phase 1

Clinical Trials (1)

NCT05026567Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo